Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpFinancial_Report.xls
10-Q - FORM 10-Q - Raptor Pharmaceutical Corpd270609d10q.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR8.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR6.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR2.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR9.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR3.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR7.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR1.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR12.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR18.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR11.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR17.htm
EX-32.1 - CERTIFICATION OF CHRISTOPHER M. STARR, PH.D. AND KIM R. TSUCHIMOTO - Raptor Pharmaceutical Corpd270609dex321.htm
EX-31.2 - CERTIFICATION OF KIM R. TSUCHIMOTO, CHIEF FINANCIAL OFFICER - Raptor Pharmaceutical Corpd270609dex312.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR5.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR14.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR13.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR19.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR10.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR15.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR16.htm
EX-31.1 - CERTIFICATION OF CHRISTOPHER M. STARR, PH.D., CHIEF EXECUTIVE OFFICER - Raptor Pharmaceutical Corpd270609dex311.htm
v2.4.0.6
Condensed Consolidated Statements Of Comprehensive Loss (USD $)
3 Months Ended 75 Months Ended
Nov. 30, 2011
Nov. 30, 2010
Nov. 30, 2011
Operating expenses:      
General and administrative $ 2,336,288 $ 1,706,099 $ 19,190,311
Research and development 5,016,178 2,695,130 44,253,468
Total operating expenses 7,352,466 4,401,229 63,443,779
Loss from operations (7,352,466) (4,401,229) (63,443,779)
Interest income 64,169 7,476 436,609
Interest expense (505) (642) (116,635)
Foreign currency transaction gain (loss) 59,499 248 88,361
Unrealized loss on short-term investments (35,309)   (35,309)
Adjustment to fair value of common stock warrants (4,168,245) (5,726,630) (26,363,708)
Net loss (11,432,857) (10,120,777) (89,434,461)
Other comprehensive income (loss)      
Foreign currency translation adjustment (8,473) 3,511 (6,569)
Comprehensive loss $ (11,441,330) $ (10,117,266) $ (89,441,030)
Net loss per share:      
Basic and diluted $ (0.25) $ (0.33)  
Weighted average shares outstanding used to compute:      
Basic and diluted 45,622,651 30,228,164